Dr. Thomas Mehrling reports

HELIX BIOPHARMA CORP. (HBP.TO) SIGNS CAPITAL RAISING AGREEMENT WITH KERENTECH CONSULTING LTD.

Helix BioPharma Corp. has signed an agreement with Kerentech Consulting Ltd., under which Kerentech will support Helix in its continuing financing efforts.

Under the terms of the agreement, Kerentech will assist Helix in closing a bridge financing round of $13-million (U.S.) to advance the company's lead therapeutic programs and strategic priorities through 2025 and beyond. The collaboration reflects Helix's commitment to accelerating efforts to secure a stable financial platform and fast-track the development of its pipeline candidates this year, beginning with its lead candidate, Tumor Defense Breaker L-DOS47.

"We're pleased to team up with Kerentech as we double down on our efforts to deliver meaningful progress in tackling hard-to-treat cancers as rapidly as possible," said Dr. Thomas Mehrling, MD, PhD, chief executive officer of Helix BioPharma. "We're seeing strong engagement from investors and are focused on bringing this round to a timely close, so we can accelerate the clinical development of L-DOS47 in combination with an immune checkpoint inhibitor and push toward better outcomes in non-small-cell lung cancer."

About Kerentech Consulting Ltd.

Kerentech Consulting is a global advisory firm specializing in strategic financing and corporate development for emerging life sciences and health care companies. With deep industry expertise and a robust investor network, Kerentech helps clients unlock capital, accelerate growth and navigate critical inflection points with confidence. The firm provides tailored support across equity and non-dilutive financing, business strategy, and partnership development, with a focus on delivering long-term value for innovative, mission-driven teams.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The company's pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumours for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed phase Ib studies in non-small-cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bispecific antibody-drug conjugates (ADCs), currently in discovery. The company also advances two pre-IND (investigational new drug) candidates: (i) Leumuna, an oral immune checkpoint modulator aimed at achieving durable remission in posttransplant leukemia relapse; and (ii) Gemceda, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

We seek Safe Harbor.